Journal of the American Academy of Dermatology
The most recent articles from:
J. Am. Acad. Dermatol.
-
J. Am. Acad. Dermatol. · Nov 2020
Randomized Controlled TrialBimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Dual neutralization of both interleukin 17A and 17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin 17A alone. ⋯ Bimekizumab response rates were maintained through week 60. A substantial proportion of patients achieved complete skin clearance. Bimekizumab was generally well tolerated.